MULTIPLE MYELOMA

Progression-free survival failed to meet the threshold for statistical significance with the addition of ixazomib to lenalidomide and dexamethasone in patients with newly diagnosed, transplant-ineligible multiple myeloma in the phase III TOURMALINE-MM2 trial, not meeting the primary endpoint.

Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.

The combination of elotuzumab plus lenalidomide and dexamethasone did not demonstrate a statistically significant improvement in progression-free survival compared with lenalidomide and dexamethasone alone in newly diagnosed patients with multiple myeloma who are transplant ineligible, missing the primary end point of the phase III ELOQUENT-1 trial.<br /> &nbsp;

The triplet combination of selinexor, bortezomib, and dexamethasone demonstrated an improved median progression-free survival rate over the standard regimen of bortezomib and dexamethasone in treating patients with multiple myeloma in the BOSTON trial

The FDA has approved the combination of isatuximab-irfc with pomalidomide and dexamethasone as treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.

Andrew J. Cowan, MD, explains the rationale for a phase I clinical trial in which a gamma-secretase inhibitor was combined with CAR T-cell therapy as treatment for heavily pretreated patients with multiple myeloma.

A supplemental Biologics License Application for daratumumab in combination with carfilzomib and dexamethasone was submitted to the FDA for consideration as treatment for relapsed/refractory multiple myeloma, according to a press release from Janssen Pharmaceuticals.

In January 2020, the FDA approved new treatment options in gastrointestinal stromal tumors, bladder cancer, and epithelioid sarcoma. The FDA also granted several Priority Review Designations, orphan drug designations, and a Fast Track designation, as well as a Breakthrough Therapy designation.

Across therapy vehicles, agents targeting the B-cell maturation antigen have emerged as promising potential therapies in the multiple myeloma treatment paradigm. Following the 2019 American Society of Hematology Annual Meeting & Exposition, experts reflect on what these new advances mean for the field of oncology care.

In an interview with&nbsp;Targeted Oncology, Noa Biran, MD, discussed the findings from 2 clinical trials evaluating consolidation therapy post-transplant in patients with high-risk multiple myeloma.

The FDA granted Priority Review to the Biologics License Application for belantamab mafodotin, an anti&ndash;B cell maturation antigen monoclonal antibody for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapies included an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, GlaxoSmithKline plc announced in a press release.<br /> &nbsp;

Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.

In an interview with&nbsp;Targeted Oncology, Andrew J. Cowan, MD, discussed the findings from the first-in-human clinical trial evaluating the combination of a GSI and BCMA CAR T cells in patients with heavily pretreated multiple myeloma. He highlighted the next steps for this research and how he sees CAR T-cell therapy evolving over the coming years.

Multiple Myeloma

Results from a phase II, open-label, multicenter study have shown that patients with heavily pretreated multiple myeloma responded to ibrutinib combined with bortezomib (Velcade) and dexamethasone.